Literature DB >> 8144292

Use of oral moist snuff and inflammatory bowel disease.

P G Persson1, G Hellers, A Ahlbom.   

Abstract

We examined the association between oral moist snuff use and inflammatory bowel disease in a case-control study based on the population in Stockholm County. The relative risk (RR) associated with ever use of moist snuff was 2.1 (95% CI: 1.0-4.6) for Crohn's disease, and 2.2 (95% CI: 1.1-4.4) for ulcerative colitis. Cigarette smoking indicated a synergistic relation with moist snuff: the RR estimate of Crohn's disease was 3.7 (95% CI: 1.1-13.1) and of ulcerative colitis 3.3 (95% CI: 1.0-10.9) for snuff dippers who were also current cigarette smokers, but only 0.9 and 1.1 respectively for snuff dippers who had never smoked.

Entities:  

Mesh:

Year:  1993        PMID: 8144292     DOI: 10.1093/ije/22.6.1101

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  10 in total

1.  Genetic polymorphisms in metabolizing enzymes modifying the association between smoking and inflammatory bowel diseases.

Authors:  Ashwin N Ananthakrishnan; Deanna D Nguyen; Jenny Sauk; Vijay Yajnik; Ramnik J Xavier
Journal:  Inflamm Bowel Dis       Date:  2014-05       Impact factor: 5.325

Review 2.  Epidemiology and risk factors for IBD.

Authors:  Ashwin N Ananthakrishnan
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-03-03       Impact factor: 46.802

3.  A qualitative study of smokers' responses to messages discouraging dual tobacco product use.

Authors:  Lucy Popova; Ganna Kostygina; Nicolas M Sheon; Pamela M Ling
Journal:  Health Educ Res       Date:  2014-01-17

4.  Alternative tobacco product use and smoking cessation: a national study.

Authors:  Lucy Popova; Pamela M Ling
Journal:  Am J Public Health       Date:  2013-03-14       Impact factor: 9.308

Review 5.  Environmental risk factors for inflammatory bowel diseases: a review.

Authors:  Ashwin N Ananthakrishnan
Journal:  Dig Dis Sci       Date:  2014-09-10       Impact factor: 3.199

6.  Testing messages to reduce smokers' openness to using novel smokeless tobacco products.

Authors:  Lucy Popova; Torsten B Neilands; Pamela M Ling
Journal:  Tob Control       Date:  2013-03-06       Impact factor: 7.552

7.  Effects of modified risk tobacco product claims on consumer comprehension and risk perceptions of IQOS.

Authors:  Bo Yang; Zachary B Massey; Lucy Popova
Journal:  Tob Control       Date:  2021-03-09       Impact factor: 6.953

8.  A National Comparison of Dual Users of Smokeless Tobacco and Cigarettes and Exclusive Cigarette Smokers, 2015-2016.

Authors:  Dina M Jones; Lucy Popova; Scott R Weaver; Terry F Pechacek; Michael P Eriksen
Journal:  Nicotine Tob Res       Date:  2018-08-14       Impact factor: 4.244

9.  Inferences beyond a claim: a typology of potential halo effects related to modified risk tobacco product claims.

Authors:  Andrew B Seidenberg; Lucy Popova; David L Ashley; Olivia A Wackowski
Journal:  Tob Control       Date:  2020-10-12       Impact factor: 7.552

10.  Smoking, use of moist snuff and risk of celiac disease: a prospective study.

Authors:  Jonas F Ludvigsson; Caroline Nordenvall; Bengt Järvholm
Journal:  BMC Gastroenterol       Date:  2014-07-03       Impact factor: 3.067

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.